CRYSTAL ROGER 4

Accession 0001385508-23-000069

CIK 0001385508other

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 9:18 AM ET

Size

26.0 KB

Accession

0001385508-23-000069

Form 4

Period: 2023-03-02

DirectorChief Executive Officer10% Owner

Transactions

Disposition to Issuer
Common Stock
2023-03-02$20.00/sh−6,667$133,340→ 0 total
Disposition to Issuer
Option
2023-03-02−150,000→ 0 total
Exercise: $5.00From: 2014-06-15Exp: 2024-06-14→ Common Stock (150,000 underlying)
Disposition to Issuer
Option
2023-03-02−25,000→ 0 total
Exercise: $6.00From: 2013-12-31Exp: 2023-12-30→ Common Stock (25,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-03-02−31,250→ 0 total
Exercise: $12.15Exp: 2031-01-26→ Common Stock (31,250 underlying)
Disposition to Issuer
Common Stock
2023-03-02$20.00/sh−37,438$748,760→ 37,901 total
Disposition to Issuer
Common Stock
2023-03-02$20.00/sh−37,901$758,020→ 0 total
Disposition to Issuer
Common Stock par value $0.001
2023-03-02$20.00/sh−5,100$102,000→ 0 total
Award
Common Stock
2023-03-02+6,667→ 6,667 total
Disposition to Issuer
Option
2023-03-02−25,000→ 0 total
Exercise: $6.00From: 2013-12-31Exp: 2023-12-30→ Common Stock (25,000 underlying)
Disposition to Issuer
Option
2023-03-02−375,000→ 0 total
Exercise: $7.25From: 2015-10-27Exp: 2025-10-26→ Common Stock (375,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-03-02−13,200→ 0 total
Exercise: $14.62Exp: 2029-01-14→ Common Stock (13,200 underlying)
Disposition to Issuer
Common Stock
2023-03-02−27,250→ 0 total
Exercise: $13.60Exp: 2030-01-07→ Common Stock (27,250 underlying)

Footnotes (5)

[F1]Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
[F2]Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 37,901 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
[F3]6,667 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer.
[F4]Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 6,667 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement.
[F5]The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.

Documents

1 file

OPIANT PHARMACEUTICALS, INC.

CIK 0001385508

Entity typeother